HROWL Company Profile and Key Details

Harrow Health, Inc. 8.625% Senior Notes due 2026 earnings surprise history is a mixed track record. The quarter that ended August 11, 2025, missed forecasts by 1603.31%. The prior quarter beat by 978.89%. Over the last six quarters, Apple has recorded several small beats. These include 75.83% in May 13, 2024.

HROWL has shown mixed momentum, losing -0.62% over the past week and -0.95% over the past quarter, though year-to-date performance is down -0.95%.

Harrow Health, Inc. 8.625% Senior Notes due 2026 last paid a dividend of 1.62 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $0.00.

Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ:HROWL) closed at $25.61 USD, gaining $0.05 (0.19%) from the previous close of $25.56. The stock is currently trading near its 52-week high $25.00 and $25.72. With a market capitalization of about $1.37 billion, Harrow Health, Inc. 8.625% Senior Notes due 2026 is classified as a small-cap and shows lower-than-market volatility (beta ~0.14). Key stats such as the average daily volume over the past year has been around 16.25 thousand shares, volume is running light vs its 52-week average. Headquartered in Nashville, DE, Harrow Health, Inc. 8.625% Senior Notes due 2026 operates in the Healthcare sector and the Medical - Pharmaceuticals industry. Led by CEO Mark L. Baum, the company employs approximately 217 people and listed since May 07, 2021. Harrow, Inc. engages in the development, production, and sale of innovative medications.

Harrow Health, Inc. 8.625% Senior Notes due 2026 (NASDAQ:HROWL) shares are flat -0.95% year-to-date Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Harrow Health, Inc. 8.625% Senior Notes due 2026 trading at a premium to the broader market with a P/E of -82.64.

Our AI price prediction model suggests that Harrow Health, Inc. 8.625% Senior Notes due 2026 stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -6.52%, with price expected at $23.94 by November 24, 2023, within a range of $23.71 to $24.15

Harrow Health, Inc. 8.625% Senior Notes due 2026 trades at a P/E ratio of -82.64, slightly below the S&P 500 average, with a price-to-sales ratio of 4.61 and a price-to-book ratio of 43.07 reflecting a rich premium to book value. The P/FCF stands at 86.6, also above market averages. Compared to sector medians, Harrow Health, Inc. 8.625% Senior Notes due 2026 P/S is trading rich, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.